Form 4: Mereo BioPharma Group PLC: General Counsel Acquires Share Options
SEC Form 4 Filing
Charles Sermon, General Counsel of Mereo BioPharma Group PLC, reports the acquisition of share options on January 25, 2025.
Summary
- Charles Sermon, the General Counsel of Mereo BioPharma Group PLC, filed a Form 4 to report changes in beneficial ownership.
- The reported transaction occurred on January 25, 2025.
- Sermon acquired 262,000 share options with an exercise price of $2.91.
- These options vest starting January 25, 2026, with 25% vesting initially and the remainder vesting in equal monthly installments over the following three years.
- Each American Depositary Share (ADS) represents five ordinary shares of the Issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock options, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity-based compensation of key personnel.
Key Dates
| Date | Description |
|---|---|
| 01/25/2025 | Date of transaction: Acquisition of share options. |
| 01/25/2026 | First vesting date for 25% of the share options. |
| 01/25/2035 | Expiration date of the share options. |
| 01/28/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.